We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kalexsyn and BioRelix Announce Extension of Collaboration to Identify Anti-Bacterial Drug Candidates
Product News

Kalexsyn and BioRelix Announce Extension of Collaboration to Identify Anti-Bacterial Drug Candidates

Kalexsyn and BioRelix Announce Extension of Collaboration to Identify Anti-Bacterial Drug Candidates
Product News

Kalexsyn and BioRelix Announce Extension of Collaboration to Identify Anti-Bacterial Drug Candidates


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Kalexsyn and BioRelix Announce Extension of Collaboration to Identify Anti-Bacterial Drug Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kalexsyn, Inc. and BioRelix, Inc., has announced that they have entered into an agreement in which KALEXSYN will provide medicinal chemistry services to drive BioRelix's ongoing research activities directed at the discovery of new anti-bacterial drugs. The terms of the agreement were not disclosed.

BioRelix is discovering and developing new treatments for infectious diseases that target riboswitches - an innovative class of RNA drug targets found in pathogenic bacteria and fungi.

"KALEXSYN has been a key collaborator on medicinal chemistry strategy and has provided high impact synthetic expertise to BioRelix for several years. We have a history of success with BioRelix and we are pleased to continue our collaboration with their research team," commented David Zimmermann, KALEXSYN chief executive officer.

Brian Dixon, Ph.D., chief executive officer of BioRelix, noted, "KALEXSYN is a premier provider of medicinal chemistry. We chose to work with KALEXSYN because of their expertise and their ability to fully engage in the scientific discovery process with our research team."

Advertisement